The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients
Journal of Clinical Immunology · 2025-12 · 45 (1)
DOI: 10.1007/s10875-025-01929-4 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Immunology, online erschienen am 01.10.2025. Verfasst von Maria Francisca Moraes-Fontes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fundação Champalimaud, Avenida Brasília, Lisboa, Portugal. francisca.fontes@fundacaochampalimaud.pt. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
INTRODUCTION: Specific determinants of target-organ damage in autoimmune diseases are complex and multifactorial, several genetic and environmental factors are recognized but mostly remain unknown. Immunotherapy with "check-point inhibitors" (CPI) is complicated by immune related adverse events (IRAE), occurring in a large fraction of patients, with organ-specific inflammation of immunologic aetiology. We hypothesized that such IRAE are associated to regulatory T cell (Treg) dysfunction. To start testing this hypothesis, we have now compared organ targets of CPI-induced IRAE with those described in IPEX (Immune dysregulation polyendocrinopathy enteropathy X-linked) patients carriers of deleterious mutations in the Foxp3 gene leading to deficient/absent Treg. METHOD: We compared the frequency of autoimmune diseases (AID) in three groups of conditions: CPI-induced IRAE, IPEX patients, and the General Population (GP) through a PubMed search from 01/01/1998 to 31/05/2024. For each group, and each autoimmune disease, the highest reported frequency was selected, listed in reference to CPI-IRAE and classified from the highest to lowest prevalence. Identified were enteropathy, rash (eczema or other dermatitis), transaminitis/hepatitis, hypothyroidism, increased lipase/exocrine pancreatitis, arthralgia/inflammatory arthritis, hypophysitis, adrenal insufficiency, type 1 diabetes mellitus, haemolytic anaemia, Sjögren´s syndrome, polymyalgia rheumatica, ankylosing spondylitis, systemic lupus erythematosus, multiple sclerosis and systemic sclerosis. RESULTS: While dermatitis and thyroid disease are also the most frequent AID in the GP, the latter, together with enteropathy, hepatitis, and adrenal insufficiency are much more frequent in CPI-IRAE and IPEX. Of note, the most frequent systemic AID in the GP such as de novo Sjögren´s syndrome, polymyalgia rheumatica, ankylosing spondylitis, systemic lupus erythematosus, multiple sclerosis and systemic sclerosis are extremely rare in CPI-IRAE (few case reports) and not described in IPEX. CONCLUSION: Our finding provides further evidence for the possibility that the functional inhibition/inactivation of Treg is a plausible contributing mechanism in the physiopathology of CPI-IRAE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fundação Champalimaud, Avenida Brasília, Lisboa, Portugal. francisca.fontes@fundacaochampalimaud.pt.
- Instituto Gulbenkian de Ciência, Oeiras, Portugal.
- Fundação Champalimaud, Avenida Brasília, Lisboa, Portugal.
Zitieren
APA
Moraes-Fontes, M. F., Demengeot, J., & Coutinho, A. (2025). The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients. Journal of Clinical Immunology, 45(1). https://doi.org/10.1007/s10875-025-01929-4
Vancouver
Moraes-Fontes MF, Demengeot J, Coutinho A. The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients. Journal of Clinical Immunology. 2025;45(1). doi:10.1007/s10875-025-01929-4
BibTeX
@article{MoraesFontes2025,
author = {Moraes-Fontes, Maria Francisca and Demengeot, Jocelyne and Coutinho, António},
title = {The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients},
journal = {Journal of Clinical Immunology},
year = {2025},
volume = {45},
number = {1},
doi = {10.1007/s10875-025-01929-4}
}
EUVIMED